Jubilant Pharmova Limited (BOM:530019)

Market Cap	136.92B -18.1%
Revenue (ttm)	86.08B +16.3%
Net Income	3.52B -23.5%
EPS	22.17 -23.5%
Shares Out	158.39M
PE Ratio	38.99
Forward PE	25.64
Dividend	5.00 (0.58%)
Ex-Dividend Date	Jul 24, 2026

Volume	23,711
Open	869.40
Previous Close	864.45
Day's Range	847.75 - 878.80
52-Week Range	783.75 - 1,183.90
Beta	0.51
Analysts	Hold
Price Target	1,088.50 (+25.69%)
Earnings Date	Aug 10, 2026

About Jubilant Pharmova

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of pulmonary embolism, cancer, coronary artery disease, and other di...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 5,657
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530019

Financial Performance

In fiscal year 2026, Jubilant Pharmova's revenue was 82.80 billion, an increase of 14.45% compared to the previous year's 72.35 billion. Earnings were 3.99 billion, a decrease of -52.53%.

Analyst Summary

According to 2 analysts, the average rating for 530019 stock is "Hold." The 12-month stock price target is ₹1,089, which is an increase of 25.69% from the latest price.

Price Target

₹1,089

(25.69% upside)

Analyst Consensus: Hold

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 17, 2026

Data Sources Report a data error